An Assessment of P-15 Bone Putty in Anterior Cervical Fusion With Instrumentation

• ClinicalTrials.gov Identifier: NCT00310440
• Recruitment Status: Completed
• First Posted: April 4, 2006
• Results First Posted: February 10, 2016
• Last Update Posted: March 12, 2020
• Sponsor: CeraPedics, Inc
• Information provided by (Responsible Party): CeraPedics, Inc

Study Description

Brief Summary:

The aim of this trial is to evaluate if P-15 bone putty (investigational device) is not inferior in effectiveness and safety to local autologous bone (control device) when applied in instrumented anterior cervical discectomy and fusion (ACDF) with use of a structural allograft ring in patients with degenerative cervical disc disease..

Condition or disease	Intervention/treatment	Phase
Intervertebral Disk Degeneration	Device: P-15 Synthetic osteoconductive bone substitute; Other: Autologous bone	Not Applicable

Detailed Description:

Anterior Cervical Discectomy and Fusion (ACDF) is a common surgical treatment option for symptomatic degenerative cervical disk disease in patients who fail conservative treatment. i-FACTOR bone graft is a unique anorganic bone mineral (ABM) and small peptide, P-15™. P-15 is a synthetic fifteen amino acid polypeptide that mimics the cell-binding domain of Type I human collagen and is responsible for osteogenic cell attachment via alpha2-beta1 integrins.

This is randomized, controlled, multi-center, prospective FDA IDE study conducted to assess the safety and effectiveness of i-FACTOR bone graft (Cerapedics, Inc. Westminster, CO) in patients treated with single level ACDF. Patients received i-FACTOR bone graft or local autologous bone inside a structural allograft.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 319 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Single (Participant)
• Primary Purpose: Treatment
• Official Title: An Assessment of P-15 Bone Putty in Anterior Cervical Fusion With Instrumentation
• Study Start Date: January 2006
• Actual Primary Completion Date: May 2014
• Actual Study Completion Date: May 23, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Bone graft substitute; Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with P-15 synthetic osteoconductive bone substitute (investigational device).	Device: P-15 Synthetic osteoconductive bone substitute; Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery; Other Name: i-Factor
Active Comparator: Autologous Bone; Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with local autologous bone.	Other: Autologous bone; Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring

Outcome Measures

Primary Outcome Measures :

1. Radiologic Fusion [ Time Frame: 12 months ]
   Successful fusion was based on roentgenographic examination showing: evidence of bridging trabecular bone between the involved motion segments, translational motion <3mm, and angular motion <5 degrees. If there was a lack of evidence of fusion on 12 month plain x-ray examination, a CT-scan was performed and final determination of the fusion status was made using the CT reading. The criteria for fusion on CT scans were: trabecular bone formation patterns within the intervertebral disc space and bridging bone formation that crosses the interspace.
2. Change in of the Overall Neck Disability Index (NDI) Score From Baseline. [ Time Frame: 12 months ]
   The NDI consists of ten items addressing functional activities (personal care, lifting, reading, work, driving, sleeping, recreational activities), pain intensity, concentration and headache. For each item, there are six potential responses, describing increasing degrees of disability (no disability = 0 to total disability = 5). An overall NDI score, out of 100, is calculated by adding up the scores for each item and multiplying by two. A higher NDI score indicates greater disability.
3. Neurologic Success [ Time Frame: 12 months ]
   The neurological endpoint is a binary variable. Neurologic success was assessed in the motor, sensory and reflex domains specific for the cervical spine as follows: maintenance or improvement of motor function in the elbow flexors (i.e. biceps muscle), elbow extensors (i.e. triceps muscle) and wrist extensors of both arms; maintenance or improvement of sensory function of both arms; maintenance or improvement of reflexes of both arms as measured at biceps tendon, triceps tendon and brachioradialis (supinator) reflex AND absence of Babinski reflex (if not present prior to surgery). Worsening of neurological status (neurological failure) was defined as a permanent decline in the subject's neurological status based on adjudication of accumulated neurological data by an independent blinded evaluator.
4. Complications [ Time Frame: 12 months ]
   Any AE within 12 months of surgery.

Secondary Outcome Measures :

1. Mean Change in Pain at Neck Visual Analog Scale (VAS). [ Time Frame: Baseline and 12 months ]
   The pain VAS is a continuous scale upon which the subject indicates their pain level ranging from "No pain at all" (0) to "Worst imaginable pain" (10). The change in pain is calculated by subtracting the 12 month score from the baseline score.
2. Mean Change at Pain at Arm and Shoulder Visual Analog Scale (VAS). [ Time Frame: Baseline and 12 months ]
   The pain VAS is a continuous scale upon which the subject indicates their pain level ranging from "No pain at all" (0) to "Worst imaginable pain" (10). The change in pain is calculated by subtracting the 12 month score from the baseline score.
3. Success Rates Measured by Aggregated Modified Odom's Criteria [ Time Frame: 12 months ]
   Subjects selected one of four categories: Excellent (Improvement Greater than or Equal to 80%, Deterioration Less than 10%), Good (Improvement Greater than or Equal to 70%, Deterioration Less than 15%), Fair (Improvement Greater than or Equal to 50%, Deterioration Less than 20%) or Poor (Improvement Less than 50%, Deterioration Greater than 20%).
4. Mean Change in the Short Form 36 v2 (SF-36v2) Physical Composite Score (PCS). [ Time Frame: Baseline and 12 months ]
   The SF-36 v2 (Medical Outcomes Trust, Boston, MA) is a multipurpose, patient-reported short-form health survey with 36 questions available in several languages. It yields two composite scores: one for physical health (Physical Composite Score - PCS) and one for mental health (Mental Composite Score - MCS) that are comprised of eight domains. The following domains make up the PCS: physical functioning, role-physical, bodily pain, general health. The PCS ranges from a score of 0 (lowest possible level of functioning) to a score of 100 (highest possible level of functioning).
5. Mean Change in the Short Form 36 v2 (SF-36v2) Mental Health Composite Score (MCS). [ Time Frame: Baseline and 12 months ]
   The SF-36 v2 (Medical Outcomes Trust, Boston, MA) is a multipurpose, patient-reported short-form health survey with 36 questions available in several languages. It yields two composite scores: one for physical health (Physical Composite Score - PCS) and one for mental health (Mental Composite Score - MCS) that are comprised of eight domains. The following domains make up the MCS: vitality, social functioning, role-emotional, mental health. The MCS ranges from a score of 0 (lowest possible level of functioning) to a score of 100 (highest possible level of functioning).
6. Kyphosis [ Time Frame: 12 months ]
   Kyphosis is evaluated in degrees.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age between 18 and 65
• Radiographically determined discogenic origin to include at least one of the following characteristics: degenerated/dark disc on MRI, decreased disc height compared to adjacent levels on radiographic film, CT, or MRI and disc herniation on CT or MRI
• Radicular symptoms by history and physical exam to include at least the following characteristics: Arm/shoulder pain, decreased flexes, decreased strength and abnormal sensation
• Pain level arm/shoulder >4 on 0-10 VAS
• Pain level neck >4 on 0-10 VAS
• Neck disability Index >30
• Involved discs between C3 and C7
• Undergoing anterior cervical fusion at a single level
• Failed to gain adequate relief from non-operative treatment
• Able and willing to give consent to participate in study
• Understand and read English at elementary level

Exclusion Criteria:

Systemic infection such as AIDS, HIV, and active hepatitis; Significant metabolic disease that in the surgeon's opinion might compromise bone growth such as osteoporosis or osteomalacia; Taking medication for the prevention of osteoporosis; Circulatory, cardiac, or pulmonary problems that could cause excessive surgical risk; Active malignancy; Nondiscogenic source of symptoms (e.g., tumor, etc.); Multiple level symptomatic degenerative disc disease; Previous cervical fusion; Previous cervical decompression at the same level; Acute cervical trauma or instability (i.e., subluxation > 3 mm on flexion/extension radiographic film); Undergoing treatment for tumor or bony traumatic injury to the cervical spine; Rheumatoid disease of the cervical spine; Myelopathy; Pregnant or planning to become pregnant in the next 2 years; Posterior cervical spine procedure scheduled; More than one level to be operated; Has a history of substance abuse (recreational drugs, alcohol); Is a prisoner; Is currently involved in a study of another investigational product for similar purpose; Has a disease process that would preclude accurate evaluation (e.g., neuromuscular disease, significant psychiatric disease).

Contacts and Locations

Locations

United States, California

Department of Neurological Surgery UCSF Spine Center

San Francisco, California, United States, 94143

United States, Colorado

Spine Education Research Institute

Thornton, Colorado, United States, 80229

United States, Florida

Sarasota Memorial Hospital

Sarasota, Florida, United States, 34233

United States, Indiana

Orthopaedics Northeast/Midwest Spine Group

Fort Wayne, Indiana, United States, 46825

Indiana Spine Group

Indianapolis, Indiana, United States, 46260

Indianapolis Neurosurgical Group

Indianapolis, Indiana, United States, 46260

United States, Kansas

Kansas University Medical Center

Kansas City, Kansas, United States, 66160-0001

United States, Massachusetts

New England Neurosurgical Associates, LLC

Springfield, Massachusetts, United States, 01104

United States, Ohio

Cleveland Clinic

Cleveland, Ohio, United States, 44195

United States, Utah

University of Utah Orthopaedic Center

Salt Lake City, Utah, United States, 84108

Canada, Alberta

Foothills Medical Center

Calgary, Alberta, Canada, T2N 2T9

Canada, Quebec

Montreal Neurological Institute

Montreal, Quebec, Canada, H3A 2B4

Sponsors and Collaborators

CeraPedics, Inc

Investigators

• Principal Investigator: Michael Janssen, MD / DO; Spine Education Research Institute

More Information

• Responsible Party: CeraPedics, Inc
• ClinicalTrials.gov Identifier: NCT00310440
• Other Study ID Numbers: 1003
• First Posted: April 4, 2006
• Results First Posted: February 10, 2016
• Last Update Posted: March 12, 2020
• Last Verified: March 2020

Keywords provided by CeraPedics, Inc:

Degenerative disc disease; P-15 Bone Putty; Bone graft; Cervical discectomy; Cervical spine

Additional relevant MeSH terms:

Intervertebral Disc Degeneration; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases